You searched for joep lange - Page 16 of 20

01 Jan Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults -60 years of age

Posted at 00:00h

Authored by: Vermeulen Joost N., Lange Joep M. A., Tyring Stephen K., Peters Patrick H., Nunez Margaret, Poland Gregory, Levin Myron J., Freeman Carrie, Chalikonda Ira, Li Jianjun, Smith Jeffrey G., Caulfield Michael J., Stek Jon E., Chan Ivan S. F., Vessey Rupert, Schödel Florian...

01 Jan Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK – II)

Posted at 00:00h

Authored by: Odusola Aina Olufemi, Hendriks Marleen, Schultsz Constance, Stronks Karien, Lange Joep, Osibogun Akin, Akande Tanimola, Alli Shade, Adenusi Peju, Agbede Kayode, Haafkens JokeIn: BMC PUBLIC HEALTH 11(1), 2011, p.171-http://www.ncbi.nlm.nih.gov/pubmed/21418629

01 Jan Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I)

Posted at 00:00h

Authored by: Hendriks Marleen, Brewster Lizzy, Wit Ferdinand, Bolarinwa Oladimeji Akeem, Odusola Aina Olufemi, Redekop William, Bindraban Navin, Vollaard Albert, Alli Shade, Adenusi Peju, Agbede Kayode, Akande Tanimola, Lange Joep, Schultsz ConstanceIn: BMC PUBLIC HEALTH 11, 2011, p.186-http://www.ncbi.nlm.nih.gov/pubmed/21439057

01 Jan “Test and Treat”: Is It Enough?

Posted at 00:00h

Authored by: Lange Joep M. A.In: CLINICAL INFECTIOUS DISEASES 52(6), 2011, p.801-802

01 Jan Immunological Analysis of Treatment Interruption After Early Highly Active Antiretroviral Therapy

Posted at 00:00h

Authored by: Schellens Ingrid M. M., Pogany Katalin, Westerlaken Geertje H. A., Borghans José A. M., Miedema Frank, van Valkengoed Irene G. M., Kroon Frank P., Lange Joep M. A., Brinkman Kees, Prins Jan M., van Baarle DebbieIn: VIRAL IMMUNOLOGY 23(6), 2010, p.609-618

01 Jan Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1 Infection

Posted at 00:00h

Authored by: Steingrover Radjin, Garcia Evian Fernandez, van Valkengoed Irene G. M., Bekker Vincent, Bezemer Daniela, Kroon Frank P., Dekker Linda, Prins Maria, de Wolf Frank, Lange Joep M. A., Prins Jan M.In: AIDS RESEARCH AND HUMAN RETROVIRUSES 26(4), 2010, p.379-387http://www.ncbi.nlm.nih.gov/pubmed/20377419

01 Jan Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa

Posted at 00:00h

Authored by: van der Borght Stefaan F., Schim van der Loeff Maarten F., Clevenbergh Philippe, Kabarega Jean Pierre, Kamo Emmanuel, van Cranenburgh Katinka, Rijckborst Henk, Lange Joep M., Rinke de Wit Tobias F.In: AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV 22(2), 2010, p.195-205http://www.ncbi.nlm.nih.gov/pubmed/20390498

01 Jan Earlier testing for HIV–how do we prevent late presentation?

Posted at 00:00h

Authored by: Yazdanpanah Yazdan, Lange Joep, Gerstoft Jan, Cairns GusIn: ANTIVIRAL THERAPY 15(Suppl. 1), 2010, p.17-24

01 Jan Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment

Posted at 00:00h

Authored by: Zhang Shuangjie, van Sighem Ard, Gras Luuk, Reiss Peter, Smit Colette, Kroon Frank, Jurriaans Suzanne, Prins Jan, Lange Joep, de Wolf FrankIn: ANTIVIRAL THERAPY 15(4), 2010, p.555-562http://www.ncbi.nlm.nih.gov/pubmed/20587848

01 Jan Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa

Posted at 00:00h

Authored by: van der Borght Stefaan F., Clevenbergh Philippe, Rijckborst Henk, Nsalou Paul, Onyia Ngozi, Lange Joep M., Rinke de Wit Tobias F., van der Loeff Maarten F. SchimIn: ANTIVIRAL THERAPY 14(1), 2009, p.63-74http://www.ncbi.nlm.nih.gov/pubmed/19320238

Search

01 Jan Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults -60 years of age

01 Jan Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK – II)

01 Jan Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I)

01 Jan “Test and Treat”: Is It Enough?

01 Jan Immunological Analysis of Treatment Interruption After Early Highly Active Antiretroviral Therapy

01 Jan Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1 Infection

01 Jan Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa

01 Jan Earlier testing for HIV–how do we prevent late presentation?

01 Jan Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment

01 Jan Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa

Contact

QUICK LINKS